Tilray Inc is a leading pharmaceutical and cannabis company that upholds a strong set of values and corporate philosophy. With a commitment to quality, innovation, and patient care, Tilray strives to provide safe and reliable medical cannabis products to individuals worldwide. The company maintains a focus on science-backed research and development, ensuring the highest standards of cultivation, production, and distribution. Tilray actively promotes transparency, integrity, and ethical practices throughout its operations. By continuously pushing boundaries and fostering collaborations, Tilray aims to improve patient access to medical cannabis, enhance healthcare outcomes, and ultimately make a positive impact on communities globally.

Tilray Inc is primarily present in several countries and regions. As a global cannabis company, Tilray has a significant presence in North America, including the United States and Canada. Furthermore, Tilray Inc has expanded its operations in Europe, particularly in Germany, Portugal, and the United Kingdom. The company's strategic partnerships and acquisitions have also allowed it to establish a foothold in Australia and South America. With its diverse international presence, Tilray Inc has positioned itself as a key player in the global cannabis industry, catering to various markets across continents.

Tilray Inc has achieved several significant milestones in its corporate history. One key achievement includes becoming the first medical cannabis producer to be GMP-certified in North America. Additionally, Tilray secured various partnerships and acquisitions to strengthen its market position and expand its global reach. The company made history by becoming the first Canadian cannabis producer to export medical cannabis to Europe, further solidifying its international presence. Tilray's listing on the NASDAQ stock exchange in 2018 marked another important milestone, showcasing its growth and credibility within the financial markets. With these achievements, Tilray Inc has positioned itself as a leading player in the global cannabis industry.

Tilray Inc is a renowned pharmaceutical and cannabis cultivation company. Established in 2013, Tilray has rapidly become a leading player in the global cannabis industry. The company is based in Canada and operates across various countries including the United States, Australia, Germany, Portugal, and more. Tilray focuses on providing innovative medical cannabis products and research, partnering with universities and researchers to drive advancements in the field. With a strong emphasis on quality and patient care, Tilray Inc has gained a reputation for its superior products and commitment to rigorous testing protocols.

The main competitors of Tilray Inc in the market include Canopy Growth Corporation, Aurora Cannabis Inc, Cronos Group Inc, and Aphria Inc.

Tilray Inc is primarily active in the cannabis industry.

Tilray Inc is a global leader in the production and distribution of cannabis products. The company operates through a vertically integrated business model, which means they handle the entire process from cultivation to distribution. Tilray focuses on creating high-quality medical cannabis products for patients, as well as recreational cannabis products for adult consumers. With state-of-the-art facilities and advanced cultivation techniques, Tilray ensures the consistent production of premium cannabis products. The company's dedication to research and development also allows them to innovate new product offerings and expand their market reach. Tilray Inc's business model aims to meet the growing demand for safe and regulated cannabis products worldwide.

Tilray Brands KGV ir -4,62.

Tilray Brands KUV ir 1,54.

AlleAktien kvalitātes vērtējums Tilray Brands ir 4/10.

gaidāmā Tilray Brands apgrozījums ir 798,84 milj. USD.

gaidāmā Tilray Brands peļņa ir -266,18 milj. USD.

Tilray Inc. is a Canada-based global corporation specializing in the production, research, development, and sale of medical cannabis. The company was founded in 2013 and has since achieved immense success. With a presence in over 20 countries, Tilray is currently one of the largest providers of medical cannabis in the global market.

Tilray Brands izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Tilray Brands vai uzņēmums nedod dividendes.

Tilray Brands ISIN ir US88688T1007.

Tilray Brands WKN ir A2JQSC.

Tilray Brands simbols ir TLRY.

Pēdējo 12 mēnešu laikā Tilray Brands maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Tilray Brands plāno maksāt dividendes 0 USD apmērā.

Tilray Brands pašreizējā dividendu rentabilitāte ir .

Tilray Brands maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Tilray Brands pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Tilray Brands tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Tilray Brands apmērā 0 USD, kas tika izmaksāta 2.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 2.08.2024..

Pēdējās dividendes izmaksa notika 2.08.2024..

Gadā 2023, Tilray Brands izmaksāja 0 USD dividendes.

Tilray Brands dividendes tiek izmaksātas USD.